![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » DR. REDDY'S LABORATORIES, INC. AND CLINTEC-INTERNATIONAL GMBH ANNOUNCE
CO-DEVELOPMENT OF ANTI-CANCER COMPOUND DRF 1042
DR. REDDY'S LABORATORIES, INC. AND CLINTEC-INTERNATIONAL GMBH ANNOUNCE CO-DEVELOPMENT OF ANTI-CANCER COMPOUND DRF 1042
Dr. Reddy's Laboratories and ClinTec International announced that they have entered into an agreement for the joint development of an anti-cancer compound, DRF 1042, belonging to the Topoisomerase inhibitors class of compounds for use as potential treatment of various types of cancer. BioSpace (http://www.biospace.com/news_story.aspx?StoryID=31375&full=1)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct